Tazeen Ahmad
Stock Analyst at B of A Securities
(3.35)
# 1,006
Out of 4,989 analysts
211
Total ratings
47.44%
Success rate
3.24%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $453 → $520 | $454.41 | +14.43% | 5 | Sep 17, 2025 | |
| INCY Incyte | Maintains: Buy | $90 → $104 | $84.54 | +23.02% | 6 | Sep 4, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $227 → $230 | $193.98 | +18.57% | 11 | Sep 2, 2025 | |
| ARGX argenx SE | Maintains: Buy | $880 → $887 | $734.39 | +20.78% | 4 | Sep 2, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Underperform | $17 → $16 | $17.93 | -10.76% | 26 | Aug 21, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $82 → $76 | $60.56 | +25.50% | 19 | Aug 20, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $126 → $134 | $98.27 | +36.36% | 9 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $23 → $24 | $23.19 | +3.49% | 8 | Jul 16, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Buy | $8 | $2.92 | +173.97% | 1 | Jul 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $73 → $95 | $98.70 | -3.75% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.82 | +91.82% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $23 | $23.60 | -2.54% | 15 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $8.31 | -51.87% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $1 → $0.8 | $0.83 | -3.43% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $13.05 | +106.90% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $7.53 | +271.85% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $68.22 | +2.61% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $7.61 | +425.62% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $146.40 | +22.27% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $13.02 | +68.97% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.95 | +53.85% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $8.16 | +83.82% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $7.35 | -72.79% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $28.40 | +167.61% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.91 | +243.64% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $0.97 | +518.49% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $12.25 | +22.45% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $24.90 | -55.82% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.38 | -40.83% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.03 | +482.52% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $12.08 | +24.17% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $48.60 | +23.46% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $2.19 | +630.59% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $14.74 | +191.72% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $204.03 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $9.35 | +3,108.56% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.00 | +351.13% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $26.21 | +83.14% | 6 | Oct 10, 2018 |
Alnylam Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $453 → $520
Current: $454.41
Upside: +14.43%
Incyte
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $84.54
Upside: +23.02%
Ascendis Pharma
Sep 2, 2025
Maintains: Buy
Price Target: $227 → $230
Current: $193.98
Upside: +18.57%
argenx SE
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $734.39
Upside: +20.78%
Sarepta Therapeutics
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $17.93
Upside: -10.76%
PTC Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $60.56
Upside: +25.50%
BioNTech SE
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $98.27
Upside: +36.36%
Apellis Pharmaceuticals
Jul 16, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $23.19
Upside: +3.49%
Taysha Gene Therapies
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $2.92
Upside: +173.97%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $98.70
Upside: -3.75%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $7.82
Upside: +91.82%
Jun 5, 2025
Maintains: Neutral
Price Target: $18 → $23
Current: $23.60
Upside: -2.54%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $8.31
Upside: -51.87%
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.83
Upside: -3.43%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $13.05
Upside: +106.90%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $7.53
Upside: +271.85%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $68.22
Upside: +2.61%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $7.61
Upside: +425.62%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $146.40
Upside: +22.27%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $13.02
Upside: +68.97%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.95
Upside: +53.85%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $8.16
Upside: +83.82%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $7.35
Upside: -72.79%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $28.40
Upside: +167.61%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.91
Upside: +243.64%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $0.97
Upside: +518.49%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $12.25
Upside: +22.45%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $24.90
Upside: -55.82%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.38
Upside: -40.83%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.03
Upside: +482.52%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $12.08
Upside: +24.17%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $48.60
Upside: +23.46%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $2.19
Upside: +630.59%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $14.74
Upside: +191.72%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $204.03
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $9.35
Upside: +3,108.56%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.00
Upside: +351.13%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $26.21
Upside: +83.14%